# Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent ESRD Trial

> **NCT02285920** · PHASE2 · COMPLETED · sponsor: **University of Pennsylvania** · enrollment: 129 (actual)

## Conditions studied

- End-Stage Renal Disease

## Interventions

- **DRUG:** Spironolactone

## Key facts

- **NCT ID:** NCT02285920
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2017-06
- **Final completion:** 2017-07-30
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2019-07-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02285920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02285920, "Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent ESRD Trial". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT02285920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*